SCHEMBL5745844

SCHEMBL5745844

Fc1cnc2ccccc2c1Cl

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 1/20 0.50
MAOB P27338 1/20 0.50
KDM4E B2RXH2 1/20 0.47
GPR3 P46089 1/20 0.47
PDE4A P27815 1/20 0.45
PDE4B Q07343 1/20 0.45
PDE4C Q08493 1/20 0.45
PDE4D Q08499 1/20 0.45
EGFR P00533 3/20 0.40
ABCG2 Q9UNQ0 1/20 0.39
NUDT1 P36639 1/20 0.38
ERN1 O75460 1/20 0.38
LMNA P02545 1/20 0.38
TP53 P04637 1/20 0.38
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37
DAO P14920 1/20 0.37
DDO Q99489 1/20 0.37
GABRA1 P14867 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28220033 0.78 MAOA (0.54) MAOAMAOBKDM4EGPR3PDE4A
SCHEMBL30583086 0.78 MAOA (0.54) MAOAMAOBKDM4EGPR3PDE4A
SCHEMBL30409628 0.75 MAOA (0.50) MAOAMAOBKDM4EGPR3PDE4A
SCHEMBL601463 0.75 MAOA (0.50) MAOAMAOBKDM4EGPR3PDE4A
SCHEMBL11295043 0.75 ERN1 (0.55) MAOAMAOBKDM4EGPR3PDE4A
SCHEMBL2125593 0.75 MAOA (0.50) MAOAMAOBKDM4EGPR3PDE4A
SCHEMBL6822558 0.75 MAOA (0.50) MAOAMAOBKDM4EGPR3PDE4A
SCHEMBL201997 0.75 MAOA (0.50) MAOAMAOBKDM4EGPR3PDE4A
SCHEMBL31384389 0.75 MAOA (0.50) MAOAMAOBKDM4EGPR3PDE4A
SCHEMBL6150432 0.75 KDM4E (0.47) KDM4EGPR3PDE4APDE4BPDE4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1578743-A4 ANTIBACTERIAL AGENTS GLAXO GROUP LTD (GB) 2006-11-29 EP disclosed
US-20060041123-A1 Antibacterial agents GLAXO GROUP LIMITED (GB) 2006-02-23 US disclosed
US-6960580-B2 Nitrogenous heterocyclic substituted quinoline compounds MILLENNIUM PHARMACEUTICALS, INC. (US) 2005-11-01 US disclosed
EP-1578743-A2 ANTIBACTERIAL AGENTS GLAXO GROUP LIMITED (GB) 2005-09-28 EP disclosed
EP-1490362-A2 (HOMO)PIPERAZINE SUBSTITUTED QUINOLINES FOR INHIBITING THE PHOSPHORYLATION OF KINASES Millennium Pharmaceuticals, Inc. (US) 2004-12-29 EP disclosed
WO-2004058144-A2 ANTIBACTERIAL AGENTS GLAXO GROUP LIMITED (GB) 2004-07-15 WO disclosed
US-20030004158-A1 Nitrogen containing heterocyclic quinoline compounds MILLENNIUM PHARMACEUTICALS, INC. 2003-01-02 US disclosed
WO-2002072578-A2 (HOMO) PIPERAZINE SUBSTITUTED QUINOLINES FOR INHIBITING THE PHOSPHORYLATION OF KINASES MILLENNIUM PHARMACEUTICALS (US) 2002-09-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030004158-A1 Nitrogen containing heterocyclic quinoline compounds WNK2, PDGFA, PDGFRA MAOA 1970/4885MAOB 1788/4885KDM4E 3084/4885
US-20060041123-A1 Antibacterial agents NQO2, NRDC, IFNG MAOA 2868/4885MAOB 3035/4885KDM4E 4544/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.